Axon 1466
CAS [844499-71-4]
MF C20H12N2O3SMW 360.39
B Cool et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metabolism. 2006, 3, 403. |
M Sanders et al. Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J. Biol. Chem. 2007, 282, 32539. |
O Göransson et al. Mechanism of Action of A-769662, a Valuable Tool for Activation of AMP-activated Protein Kinase. J. Biol. Chem. 2007, 282, 32549-32560. |
JW Scott et al. Thienopyridone drugs are selective activators of AMP-activated protein kinase β1-containing complexes. Chem. Biol. 2008, 15, 1220. |
JT Treebak et al. A-769662 activates AMPK β1-containing complexes but induces glucose uptake through a PI3 kinase-dependent pathway in mouse skeletal muscle. Am. J. Physiol. Cell Physiol. 2009, 297(4), C1041-C1052. |
6,7-Dihydro-4-hydroxy-3-(2"-hydroxy[1,1"-biphenyl]-4-yl )-6-oxo-thieno[2,3-b]pyridine-5-carbonitrile
[844499-71-4]
Axon Medchem的业务之一,是独有的Axon Ligands配体库,在世界范围内,被认为是药物研发的标准。这其中,针对850余种生物靶标(包括细胞信号、基因转录、凋亡、细胞周期调控、CNS等),Axon Medchem拥有多达2000余种小分子抑制剂或调节剂。除了配体库,Axon Medchem还是欧洲著名的CRO公司,主要针对生物活性分子和药物类似分子展开合成及协议开发工作,在过去的10年中,Axon Medchem已经发现了多种潜在药物分子,并在生物医药界享有一定的声誉。